| Статус: | Unknown status |
| Фаза: | Phase 2 |
| Начало: | 30 апреля 2020 г. |
| Окончание: | 30 октября 2020 г. |
| Описание: | This single-center, prospective, open-label, comparator study, blind for central accessor evaluates the efficacy, safety of inhalations of low-doses of melphalan in patients with pneumonia with confirmed or suspected COVID-19. All patients will receive 0,1 mg of melphalan in 7-10 daily inhalations 1 time per day. |
| смотреть на ClinicalTrials.gov |
| Статус: | Unknown status |
| Фаза: | Phase 2 |
| Начало: | 30 апреля 2020 г. |
| Окончание: | 30 октября 2020 г. |
| Описание: | This single-center, prospective, open-label, comparator study, blind for central accessor evaluates the efficacy, safety of inhalations of low-doses of melphalan in patients with pneumonia with confirmed or suspected COVID-19. All patients will receive 0,1 mg of melphalan in 7-10 daily inhalations 1 time per day. |
| смотреть на ClinicalTrials.gov |
| Статус: | Unknown status |
| Фаза: | N/A |
| Начало: | 24 апреля 2019 г. |
| Окончание: | 1 октября 2020 г. |
| Описание: | Interventional open-labeled study in parallel groups is aimed to evaluate changes of beta receptors in healthy volunteers under the influence of inhaled metacholine, long-acting anticholinergics and beta-agonists using modified radioligand method. |
| смотреть на ClinicalTrials.gov |
| Статус: | Unknown status |
| Фаза: | N/A |
| Начало: | 24 апреля 2019 г. |
| Окончание: | 1 октября 2020 г. |
| Описание: | Interventional open-labeled study in parallel groups is aimed to evaluate changes of beta receptors in healthy volunteers under the influence of inhaled metacholine, long-acting anticholinergics and beta-agonists using modified radioligand method. |
| смотреть на ClinicalTrials.gov |
| Статус: | Unknown status |
| Фаза: | Phase 2 |
| Начало: | 20 июня 2018 г. |
| Окончание: | 30 декабря 2021 г. |
| Описание: | This non-randomised open-label prospective pilot study evaluates the safety and efficacy of inhalations of ultra-low doses of alkylating drug melphalan for the treatment of non-cystic fibrosis bronchiectasis. All patients will receive 0,1 mg of melphalan in 5 daily inhalations 1 time per day. |
| смотреть на ClinicalTrials.gov |